Neurocrine bets nearly $3bn on deal for insatiable hunger treatment

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome


Source: Read full article on ft.com


Discover more from Daily Financial Markets

Subscribe to get the latest posts sent to your email.

Leave a Reply

Your email address will not be published. Required fields are marked *